CSIMarket
 
Merus N v   (NASDAQ: MRUS)
 
Price: $90.0000 $-6.92 -7.140%
Day's High: $96.86 Week Perf: -7.17 %
Day's Low: $ 87.14 30 Day Perf: -6.34 %
Volume (M): 2,728,600 52 Wk High: $ 97.14
Volume (M$): $ 245,574 52 Wk Avg: $90.11
Open: $96.86 52 Wk Low: $65.74



 Market Capitalization (Millions $) 6,811
 Shares Outstanding (Millions) 76
 Employees 105
 Revenues (TTM) (Millions $) 57
 Net Income (TTM) (Millions $) -381
 Cash Flow (TTM) (Millions $) -66
 Capital Exp. (TTM) (Millions $) 1

Business Description


Merus N is a company that specializes in creating high-quality products for use in the health and wellness industry. They are known for their innovative and unique approach to developing effective solutions for various health concerns.

Merus N focuses on using natural ingredients and advanced scientific research to create their products. They prioritize safety and efficacy, ensuring that their customers receive the best possible results.

Their product range includes dietary supplements, skincare products, and personal care items. These products are formulated to address specific health issues such as immune support, digestive health, stress management, and anti-aging.

Merus N emphasizes the use of sustainable and environmentally friendly practices in their manufacturing processes. They are dedicated to creating products that are both beneficial for consumers and respectful of the planet.

Overall, Merus N is committed to providing high-quality health and wellness solutions that enhance people's lives and promote overall well-being.


   Company Address: Uppsalalaan 17 Utrecht 3584
   Company Phone Number: 016 2500   Stock Exchange / Ticker: NASDAQ MRUS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY        0.36% 
KPTI   -4.28%    
MDGL        1.37% 
MGNX        6.54% 
RYTM   -4.13%    
SUPN   -0.46%    
• View Complete Report
   



Clinical Study

Innovations in Immunotherapy SYNC-T and Merus Lead the Charge Against Advanced Cancers,

Published Sat, May 24 2025 8:46 PM UTC

Immunotherapy Advances: SYNC-T for Prostate Cancer and Merus for Head and Neck Cancer In recent developments in cancer therapeutics, innovative immunotherapy treatments have shown promising efficacy, highlighting a transformative era in managing metastatic cancers. Notably, Syncromune Inc. announced at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 tha...

Product Service News

Merus Advances Cancer Treatment Paradigms with Petosemtamab and FDA Approval of BIZENGRI A Dual Milestone in Oncolog...

Published Thu, May 15 2025 1:16 PM UTC

In a significant leap for oncology research and treatment, Merus N.V. an innovative clinical-stage biotechnology company headquartered in Utrecht, The Netherlands, and Cambridge, Massachusetts, has made remarkable strides with its cutting-edge approaches in harnessing multispecific antibodies. The company recently announced pivotal developments regarding two of its leading c...

Product Service News

Advancements in Oncology Merus Initiates Phase 2 Trial of Petosemtamab in Metastatic Colorectal Cancer

Published Sun, Dec 29 2024 5:57 PM UTC

The landscape of oncology is continually evolving, propelled by innovative therapies and clinical trials aimed at addressing hard-to-treat conditions. In a noteworthy development, Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, has initiated a Phase 2 trial of its promising monoclonal antibody, petosemtamab, for patients with heavily pretreated metastatic color...

Product Service News

Unlocking Wealth The Heirs Rights Property Report and Its Implications for Indianas Future

Published Tue, Dec 17 2024 4:41 PM UTC

In a significant collaboration aimed at addressing the complexities of property transfers and ownership rights, the Federal Home Loan Bank of Indianapolis (FHLBI) and Black Onyx Management recently released the Heirs Rights Property Report, focusing on major counties throughout Indiana. This report brings to light the often-overlooked implications of property rights when it ...

Clinical Study

Merus N.V.s Petosemtamab Shows Promise in Head and Neck Cancer Treatment

Published Sat, Dec 7 2024 6:30 AM UTC

Merus N.V. a clinical-stage immuno-oncology company, has released interim data showcasing the efficacy of its novel antibody, Petosemtamab, in second-line or later (2L+) recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). This data indicates clinically meaningful activity in this challenging-to-treat cancer population. Concurrently, the company reported ...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 120.32
Price to Sales (Expected) -
Price to Book 8.79
PEG (TTM) -

Financial Strength Current
Quick Ratio 9.52
Working Capital Ratio 10.21
Leverage Ratio (MRQ) 0.17
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -5.37 $
Revenues (TTM) 0.75 $
Cash Flow (TTM) -
Cash 10.92 $
Book Value 10.24 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 539,105
Net Income per Employee (TTM) -3,629,857
Receivable Turnover Ratio (TTM) 4.39
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.06

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -794.06 %
Net Margin (MRQ) -786.17 %
Net Cash Flow Margin (MRQ) -619.74 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Merus N V's Segments
Segment    100 % of total Revenue
Collaboration Revenue    97.67 % of total Revenue
Collaboration Revenue Segment    97.67 % of total Revenue
Royalty Revenue    2.33 % of total Revenue
Royalty Revenue Segment    2.33 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.